Cheng Wei, Li Fen, Tian Jing, Xie Xi, Chen Jin-Wei, Peng Xiao-Fei, Tang Qi, Ge Yan
Department of Rheumatology and Immunology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
J Inflamm Res. 2022 Apr 13;15:2365-2380. doi: 10.2147/JIR.S353539. eCollection 2022.
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments.
滑膜炎、痤疮、脓疱病、骨肥厚、骨炎（SAPHO）综合征是一种罕见的自身炎症性疾病，其特征为皮肤病学紊乱和骨关节炎症性病变。本文基于治疗靶点和分子大小综述了生物制剂及其他治疗方法在SAPHO综合征中的应用。我们发现，药物尤其是生物制剂，对骨骼、关节和皮肤损伤有不同的作用。这可能与SAPHO患者骨关节和皮肤症状所涉及的不同炎症途径有关。在本研究中，我们为SAPHO综合征提供分层用药建议。有骨关节症状的患者可考虑使用肿瘤坏死因子阻滞剂、JAK抑制剂、白细胞介素（IL）-1抑制剂和IL-17抑制剂。有皮肤症状的患者应考虑使用IL-17和JAK抑制剂。阿普司特、雷公藤和双膦酸盐是其他有效的治疗方法。
